Mineralys Therapeutics Key Executives
This section highlights Mineralys Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Mineralys Therapeutics
(Showing 0 of )
Mineralys Therapeutics Earnings
This section highlights Mineralys Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-12 | $-1.00 | $-0.98 |
| Read Transcript | Q3 | 2024 | 2024-11-11 | $-0.83 | $-1.13 |
| Read Transcript | Q2 | 2024 | 2024-08-13 | $-0.73 | $-0.83 |
| Read Transcript | Q1 | 2024 | 2024-05-09 | $-0.68 | $-0.70 |
| Read Transcript | Q4 | 2023 | 2024-03-21 | $-0.85 | $-0.61 |
| Read Transcript | Q3 | 2023 | 2023-11-12 | N/A | N/A |
| Read Transcript | Q2 | 2023 | 2023-08-12 | N/A | N/A |
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
$15.31
Stock Price
$961.24M
Market Cap
51
Employees
Radnor, PA
Location
Financial Statements
Access annual & quarterly financial statements for Mineralys Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $168.58M | $70.36M | $26.25M | $16.31M | $2.41M |
| General and Administrative Expenses | $23.82M | $14.30M | $5.23M | $2.42M | $532.00K |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $23.82M | $14.30M | $5.23M | $2.42M | $532.00K |
| Other Expenses | $- | $- | $4.00K | $1.00K | $-1.00K |
| Operating Expenses | $192.40M | $84.66M | $31.48M | $18.73M | $2.94M |
| Cost and Expenses | $- | $84.66M | $31.48M | $18.73M | $2.94M |
| Interest Income | $- | $12.76M | $1.68M | $- | $- |
| Interest Expense | $- | $- | $1.68M | $27.00K | $115.00K |
| Depreciation and Amortization | $- | $- | $228.49K | $18.73M | $2.94M |
| EBITDA | $-192.40M | $-84.66M | $-31.48M | $- | $- |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-192.40M | $-84.66M | $-31.48M | $-18.73M | $-2.94M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $14.59M | $12.76M | $1.68M | $-683.00K | $-483.00K |
| Income Before Tax | $-177.81M | $-71.90M | $-29.80M | $-19.41M | $-3.43M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $-1.90M | $27.00K | $115.00K |
| Net Income | $-177.81M | $-71.90M | $-29.80M | $-19.41M | $-3.43M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-3.66 | $-1.99 | $-0.73 | $-0.50 | $-0.09 |
| EPS Diluted | $-3.66 | $-1.99 | $-0.73 | $-0.50 | $-0.09 |
| Weighted Average Shares Outstanding | 48.54M | 36.19M | 40.86M | 39.06M | 39.06M |
| Weighted Average Shares Outstanding Diluted | 48.54M | 36.19M | 40.86M | 39.06M | 39.06M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $9.00K | $8.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-9.00K | $-8.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $44.57M | $53.98M | $39.27M | $30.75M | $23.68M | $22.50M | $11.88M | $12.29M | $7.82M | $6.06M | $5.59M | $6.78M | $6.62M |
| General and Administrative Expenses | $7.20M | $6.12M | $5.89M | $4.61M | $4.03M | $3.77M | $3.85M | $2.65M | $2.19M | $1.36M | $884.00K | $791.00K | $467.00K |
| Selling and Marketing Expenses | $- | $- | $- | $-8.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $7.20M | $6.12M | $5.89M | $4.60M | $4.03M | $3.77M | $3.85M | $2.65M | $2.19M | $1.36M | $884.00K | $791.00K | $467.00K |
| Other Expenses | $- | $- | $- | $1.00K | $1.00K | $- | $1.00K | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $51.77M | $60.11M | $45.17M | $35.35M | $27.71M | $26.27M | $15.73M | $14.94M | $10.01M | $7.42M | $6.48M | $7.57M | $7.08M |
| Cost and Expenses | $51.77M | $60.11M | $45.17M | $35.36M | $27.71M | $26.27M | $15.73M | $14.94M | $10.01M | $7.42M | $6.48M | $7.57M | $7.08M |
| Interest Income | $2.81M | $3.77M | $4.15M | $3.85M | $3.32M | $3.51M | $3.59M | $2.33M | $935.00K | $741.00K | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $1.68M | $- | $- | $- | $- |
| Depreciation and Amortization | $15.00K | $11.00K | $9.00K | $8.00K | $43.81K | $-39.59K | $122.08K | $- | $10.01M | $7.42M | $6.48M | $7.57M | $7.08M |
| EBITDA | $-51.75M | $-60.09M | $-45.16M | $-35.35M | $-27.71M | $-26.27M | $-15.73M | $-14.94M | $-10.01M | $- | $-6.48M | $- | $-7.08M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-51.77M | $-60.11M | $-45.17M | $-35.36M | $-27.71M | $-26.27M | $-15.73M | $-14.94M | $-10.01M | $-7.42M | $-6.48M | $-7.57M | $-7.08M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $2.82M | $3.76M | $4.15M | $3.85M | $3.32M | $3.51M | $3.59M | $2.33M | $935.00K | $745.00K | $- | $- | $- |
| Income Before Tax | $-48.95M | $-56.34M | $-41.01M | $-31.51M | $-24.39M | $-22.76M | $-12.14M | $-12.61M | $-9.07M | $-6.68M | $-6.48M | $-7.57M | $-7.08M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $- | $-35.28K | $-43.81K | $39.59K | $-3.72M | $- | $-10.01K | $-7.42K | $-6.48K | $-7.57M | $-7.08M |
| Net Income | $-48.95M | $-56.34M | $-41.01M | $-31.51M | $-24.39M | $-22.76M | $-12.14M | $-12.61M | $-9.07M | $-6.68M | $-6.48M | $-7.57M | $-7.08M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.98 | $-1.13 | $-0.83 | $-0.70 | $-0.61 | $-0.55 | $-0.30 | $-0.51 | $-0.22 | $-1288.94 | $-0.35 | $-0.41 | $-0.18 |
| EPS Diluted | $-0.98 | $-1.13 | $-0.83 | $-0.70 | $-0.61 | $-0.55 | $-0.30 | $-0.51 | $-0.22 | $-1288.84 | $-0.35 | $-0.41 | $-0.18 |
| Weighted Average Shares Outstanding | 49.96M | 49.82M | 49.36M | 44.90M | 40.09M | 41.11M | 40.86M | 24.76M | 40.86M | 5.18K | 18.64M | 18.64M | 39.06M |
| Weighted Average Shares Outstanding Diluted | 49.96M | 49.82M | 49.36M | 44.90M | 40.09M | 41.11M | 40.86M | 24.76M | 40.86M | 5.18K | 18.64M | 18.64M | 39.06M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $114.09M | $49.30M | $87.70M | $10.61M | $1.41M |
| Short Term Investments | $84.10M | $187.26M | $22.41M | $- | $- |
| Cash and Short Term Investments | $198.19M | $236.57M | $110.11M | $10.61M | $1.41M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $7.16M | $12.54M | $2.70M | $460.00K | $57.00K |
| Total Current Assets | $205.35M | $249.10M | $110.11M | $11.12M | $1.47M |
| Property Plant Equipment Net | $53.00K | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $2.48M | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $499.00K | $51.00K | $4.33M | $3.00K | $20.00K |
| Total Non-Current Assets | $552.00K | $2.53M | $4.33M | $3.00K | $20.00K |
| Other Assets | $- | $- | $0 | $- | $- |
| Total Assets | $205.90M | $251.64M | $114.44M | $11.12M | $1.49M |
| Account Payables | $479.00K | $601.00K | $1.91M | $763.00K | $529.00K |
| Short Term Debt | $- | $- | $- | $- | $4.50M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $14.17M | $9.88M | $6.16M | $4.29M | $54.00K |
| Total Current Liabilities | $14.65M | $10.48M | $8.07M | $5.05M | $5.08M |
| Long Term Debt | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $- | $158.64M | $29.00M | $- |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $14.65M | $10.48M | $166.71M | $34.05M | $5.08M |
| Preferred Stock | $- | $- | $158.64M | $29.00M | $- |
| Common Stock | $5.00K | $4.00K | $1.00K | $1.00K | $1.00K |
| Retained Earnings | $-302.52M | $-124.71M | $-52.81M | $-23.01M | $-3.60M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $-158.64M | $-0 | $0 |
| Other Total Stockholders Equity | $493.77M | $365.86M | $52.81M | $-29.00M | $5.00K |
| Total Stockholders Equity | $191.26M | $241.15M | $-52.27M | $-22.93M | $-3.60M |
| Total Equity | $191.26M | $241.15M | $-52.27M | $-22.93M | $-3.60M |
| Total Liabilities and Stockholders Equity | $205.90M | $251.64M | $114.44M | $11.12M | $1.49M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $205.90M | $251.64M | $114.44M | $11.12M | $1.49M |
| Total Investments | $84.10M | $189.75M | $22.41M | $- | $- |
| Total Debt | $- | $- | $- | $- | $4.50M |
| Net Debt | $-114.09M | $-49.30M | $-87.70M | $-10.61M | $3.09M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | March 31, 2022 | December 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $114.09M | $97.27M | $67.86M | $90.42M | $49.30M | $265.89M | $101.14M | $138.25M | $87.70M | $48.95M | $-10.61M | $10.61M |
| Short Term Investments | $84.10M | $166.33M | $243.26M | $248.15M | $187.26M | $167.46M | $159.96M | $132.39M | $22.41M | $72.00M | $21.22M | $- |
| Cash and Short Term Investments | $198.19M | $263.60M | $311.12M | $338.56M | $236.57M | $265.89M | $261.10M | $270.64M | $110.11M | $120.95M | $10.61M | $10.61M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $7.16M | $- | $6.89M | $8.25M | $12.54M | $23.23M | $8.39M | $4.63M | $2.70M | $933.00K | $- | $460.00K |
| Total Current Assets | $205.35M | $267.73M | $318.00M | $346.82M | $249.10M | $265.38M | $269.49M | $275.27M | $110.11M | $121.89M | $10.61M | $11.12M |
| Property Plant Equipment Net | $53.00K | $69.00K | $42.00K | $51.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $2.48M | $12.13M | $21.68M | $31.12M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $499.00K | $452.00K | $449.00K | $379.00K | $51.00K | $51.00K | $51.00K | $39.00K | $4.33M | $564.00K | $-10.61M | $3.00K |
| Total Non-Current Assets | $552.00K | $521.00K | $491.00K | $430.00K | $2.53M | $12.18M | $21.73M | $31.16M | $4.33M | $564.00K | $-10.61M | $3.00K |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $0 | $- | $- | $- |
| Total Assets | $205.90M | $268.25M | $318.49M | $347.25M | $251.64M | $277.56M | $291.22M | $306.44M | $114.44M | $122.45M | $- | $11.12M |
| Account Payables | $479.00K | $3.11M | $1.71M | $4.26M | $601.00K | $5.57M | $2.20M | $2.39M | $1.91M | $2.56M | $- | $763.00K |
| Short Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $14.17M | $28.21M | $26.69M | $14.94M | $9.88M | $7.97M | $4.01M | $8.17M | $6.16M | $4.66M | $- | $4.29M |
| Total Current Liabilities | $14.65M | $31.32M | $28.40M | $19.20M | $10.48M | $13.54M | $6.21M | $10.56M | $8.07M | $7.22M | $- | $5.05M |
| Long Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $158.64M | $- | $- |
| Total Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $158.64M | $158.64M | $- | $29.00M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $14.65M | $31.32M | $28.40M | $19.20M | $10.48M | $13.54M | $6.21M | $10.56M | $166.71M | $165.86M | $- | $34.05M |
| Preferred Stock | $- | $- | $- | $1 | $251.64M | $277.56M | $- | $- | $158.64M | $158.64M | $29.00M | $29.00M |
| Common Stock | $5.00K | $5.00K | $5.00K | $5.00K | $4.00K | $4.00K | $4.00K | $4.00K | $1.00K | $1.00K | $- | $1.00K |
| Retained Earnings | $-302.52M | $-253.57M | $-197.23M | $-156.22M | $-124.71M | $-100.32M | $-77.56M | $-65.42M | $-52.81M | $-43.74M | $- | $-23.01M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $0 | $0 | $-251.64M | $-277.56M | $-0 | $- | $-158.64M | $- | $-22.93M | $-0 |
| Other Total Stockholders Equity | $493.77M | $490.50M | $487.32M | $484.26M | $365.86M | $641.88M | $362.56M | $361.29M | $52.81M | $-158.32M | $- | $-28.91M |
| Total Stockholders Equity | $191.26M | $236.93M | $290.10M | $328.05M | $241.15M | $264.01M | $285.01M | $295.88M | $-52.27M | $-43.41M | $6.07M | $-22.93M |
| Total Equity | $191.26M | $236.93M | $290.10M | $328.05M | $241.15M | $264.01M | $285.01M | $295.88M | $-52.27M | $-43.41M | $6.07M | $-22.93M |
| Total Liabilities and Stockholders Equity | $205.90M | $268.25M | $318.49M | $347.25M | $251.64M | $277.56M | $291.22M | $306.44M | $114.44M | $122.45M | $6.07M | $11.12M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $205.90M | $268.25M | $318.49M | $347.25M | $251.64M | $277.56M | $291.22M | $306.44M | $114.44M | $122.45M | $6.07M | $11.12M |
| Total Investments | $84.10M | $166.33M | $243.26M | $248.15M | $189.75M | $12.13M | $181.63M | $163.51M | $22.41M | $72.00M | $21.22M | $- |
| Total Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $-114.09M | $-97.27M | $-67.86M | $-90.42M | $-49.30M | $-265.89M | $-101.14M | $-138.25M | $-87.70M | $-48.95M | $10.61M | $-10.61M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-177.81M | $-71.90M | $-29.80M | $-19.41M | $-3.43M |
| Depreciation and Amortization | $43.00K | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $11.34M | $5.06M | $455.00K | $80.00K | $1.00K |
| Change in Working Capital | $9.52M | $-7.47M | $772.00K | $4.08M | $480.00K |
| Accounts Receivables | $424.00K | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $3.01M | $- | $- |
| Other Working Capital | $9.10M | $-7.47M | $772.00K | $4.08M | $480.00K |
| Other Non Cash Items | $-9.40M | $-6.87M | $-649.00K | $684.00K | $482.00K |
| Net Cash Provided by Operating Activities | $-166.31M | $-81.17M | $-29.22M | $-14.56M | $-2.46M |
| Investments in Property Plant and Equipment | $-96.00K | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $-373.44M | $-347.97M | $-71.76M | $- | $- |
| Sales Maturities of Investments | $488.50M | $187.50M | $50.00M | $- | $- |
| Other Investing Activities | $- | $- | $-21.76K | $- | $- |
| Net Cash Used for Investing Activities | $114.96M | $-160.47M | $-21.76M | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $116.06M | $202.99M | $- | $23.81M | $-20.00K |
| Common Stock Repurchased | $- | $- | $-1.63M | $- | $-20.00K |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $83.00K | $516.00K | $129.65M | $23.81M | $3.83M |
| Net Cash Used Provided by Financing Activities | $116.14M | $203.25M | $128.02M | $23.81M | $3.83M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $64.79M | $-38.40M | $77.04M | $9.25M | $1.37M |
| Cash at End of Period | $114.09M | $49.30M | $87.70M | $10.66M | $1.41M |
| Cash at Beginning of Period | $49.30M | $87.70M | $10.66M | $1.41M | $42.00K |
| Operating Cash Flow | $-166.31M | $-81.17M | $-29.22M | $-14.56M | $-2.46M |
| Capital Expenditure | $-96.00K | $- | $- | $- | $- |
| Free Cash Flow | $-166.41M | $-81.17M | $-29.22M | $-14.56M | $-2.46M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-48.95M | $-56.34M | $-41.01M | $-31.51M | $-24.39M | $-22.76M | $-12.14M | $-12.61M | $-9.07M | $-6.68M | $-6.48M | $-7.57M | $-7.08M |
| Depreciation and Amortization | $15.00K | $11.00K | $9.00K | $8.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $3.13M | $6.01M | $2.87K | $2.19M | $1.46M | $1.58M | $1.28M | $749.00K | $218.00K | $192.00K | $26.00K | $19.00K | $16.00K |
| Change in Working Capital | $-19.71M | $-23.51M | $10.83M | $12.68M | $-3.98M | $4.11M | $-7.54M | $-61.00K | $-921.00K | $-263.00K | $984.00K | $972.00K | $2.18M |
| Accounts Receivables | $98.00K | $23.00K | $184.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $8.40M | $503.00K | $- | $- | $- | $3.01M | $- | $- | $- | $- |
| Other Working Capital | $-19.81M | $-23.54M | $10.65M | $12.68M | $-3.98M | $4.11M | $-7.54M | $-61.00K | $-921.00K | $-263.00K | $984.00K | $108 | $157 |
| Other Non Cash Items | $-1.34M | $23.65M | $22.13K | $-302.00K | $-2.07M | $-1.96M | $-1.98M | $-855.00K | $-410.00K | $-239.00K | $1.03K | $864 | $2.02K |
| Net Cash Provided by Operating Activities | $-66.84M | $-50.19M | $-30.15M | $-19.14M | $-28.98M | $-19.03M | $-20.39M | $-12.78M | $-10.19M | $-6.99M | $-5.47M | $-6.58M | $-4.89M |
| Investments in Property Plant and Equipment | $- | $-37.00K | $- | $-59.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-63.93M | $-58.86M | $-127.26M | $-123.39M | $-73.09M | $-55.99M | $-56.14M | $-162.75M | $- | $-71.76M | $- | $- | $- |
| Sales Maturities of Investments | $147.50M | $138.50M | $135.00M | $67.50M | $65.00M | $60.00M | $40.00M | $22.50M | $50.00M | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $-55.89K | $-8.09K | $4.01K | $-16.14K | $- | $50.00M | $-71.76K | $- | $- | $- |
| Net Cash Used for Investing Activities | $83.57M | $79.61M | $7.74M | $-55.95M | $-8.09M | $4.01M | $-16.14M | $-140.25M | $50.00M | $-71.76M | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $6.00K | $-60.00K | $116.12M | $74.00K | $184.00K | $-581.00K | $203.57M | $11.99M | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $138.00K | $- | $- | $64.58K | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $90.00K | $-1.00K | $-92.00K | $86.00K | $74.00K | $184.00K | $- | $- | $-1.07M | $- | $117.65M | $12.00M | $- |
| Net Cash Used Provided by Financing Activities | $90.00K | $-1.00K | $-152.00K | $116.20M | $74.00K | $184.00K | $-581.00K | $203.57M | $-1.07M | $-561.00K | $117.65M | $12.00M | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $16.82M | $29.42M | $-22.56M | $41.11M | $-37.00M | $-14.84M | $-37.11M | $50.55M | $38.75M | $-79.31M | $112.18M | $5.42M | $-4.89M |
| Cash at End of Period | $114.09M | $97.27M | $67.86M | $90.42M | $49.30M | $86.30M | $101.14M | $138.25M | $87.70M | $48.95M | $128.26M | $16.08M | $10.66M |
| Cash at Beginning of Period | $97.27M | $67.86M | $90.42M | $49.30M | $86.30M | $101.14M | $138.25M | $87.70M | $48.95M | $128.26M | $16.08M | $10.66M | $15.55M |
| Operating Cash Flow | $-66.84M | $-50.19M | $-30.15M | $-19.14M | $-28.98M | $-19.03M | $-20.39M | $-12.78M | $-10.19M | $-6.99M | $-5.47M | $-6.58M | $-4.89M |
| Capital Expenditure | $- | $-37.00K | $- | $-59.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Free Cash Flow | $-66.84M | $-50.22M | $-30.15M | $-19.20M | $-28.98M | $-19.03M | $-20.39M | $-12.78M | $-10.19M | $-6.99M | $-5.47M | $-6.58M | $-4.89M |
Mineralys Therapeutics Dividends
Explore Mineralys Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Mineralys Therapeutics News
Read the latest news about Mineralys Therapeutics, including recent articles, headlines, and updates.
Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile –
Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET
Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension Luke Laffin, MD, Cleveland Clinic, to discuss latest data from the pivotal Advance-HTN and Launch-HTN clinical trials and the potential of lorundrostat in hypertension
Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
RADNOR, Pa., March 18, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the closing of the sale of an additional 1,944,444 shares of its common stock at a public offering price of $13.50 per share pursuant to the exercise in full of the underwriters' option to purchase additional shares in connection with Mineralys' recently completed public offering. After giving effect to the sale of these additional shares, the aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $201.2 million. All of the securities sold in the offering were sold by Mineralys.
Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo
RADNOR, Pa., March 17, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea and other diseases driven by dysregulated aldosterone, today announced that data from the Phase 2 Advance-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25), which is being held in Chicago on March 29-31, 2025.
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
RADNOR, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten public offering of 12,962,962 shares of its common stock at a public offering price of $13.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $175.0 million. In addition, Mineralys has granted the underwriters a 30-day option to purchase up to an additional 1,944,444 shares of its common stock. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is expected to close on or about March 13, 2025, subject to the satisfaction of customary closing conditions.
Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met with statistical significance. Upcoming catalysts include the full data release from Advance-HTN in March 2025 and phase 2 Explore-CKD trial results in Q2 2025. Financially, company has $198.2 million in cash but may need to raise funds soon, potentially diluting shareholders.
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock
RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that it has commenced an underwritten public offering of $250.0 million of shares of its common stock. In addition, Mineralys expects to grant the underwriters a 30-day option to purchase up to an additional $37.5 million of shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate
On Monday, Mineralys Therapeutics, Inc. MLYS released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials of lorundrostat for uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension
– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at week 6 – – Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction in systolic blood pressure, and an 11.7 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at end of treatment, week 12 – – Advance-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a highly statistically significant 7.9 mmHg placebo-adjusted reduction assessed by 24hr ABPM at end of treatment, week 12 – – Lorundrostat demonstrated a favorable safety and tolerability profile in both pivotal trials – – Full results from Advance-HTN to be presented on March 29, 2025, at the American College of Cardiology Scientific Sessions – – Conference call today at 8:00 a.m. ET – RADNOR, Pa.
Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 8:00 AM ET
RADNOR, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will host a conference call and webinar to announce topline results from its Launch-HTN and Advance-HTN pivotal trials on Monday, March 10, 2025, at 8:00 a.m. ET.
Mineralys Therapeutics, Inc. (MLYS) Q4 2024 Earnings Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q4 2024 Results Conference Call February 12, 2025 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore ISI Rich Law - Goldman Sachs Annabel Samimy - Stifel Mohit Bansal - Wells Fargo Rami Khadkar - LifeSci Capital Matthew Caufield - H. C. Wainwright Operator Good morning, ladies and gentlemen, and welcome to the Mineralys Fourth Quarter and Full Year 2024 Earnings Conference Call.
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025
RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2024, before the financial markets open on Wednesday, February 12, 2025.
Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension
I believe Mineralys Therapeutics has a promising candidate with Lorundrostat for hypertension, CKD, and OSA. It should report more key pivotal clinical data this year. MLYS has several Phase 2 and 3 trials on Lorundrostat that could position it favorably for a potential FDA submission by late 2026 or sometime in 2027. According to the company's slides, Lorundrostat seems to have superior selectivity in some patients that reduces cortisol suppression and other side effects.
Mineralys Therapeutics, Inc. (MLYS) Q3 2024 Earnings Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q3 2024 Earnings Conference Call November 11, 2024 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors Jon Congleton - Chief Executive Officer Adam Levy - Chief Financial Officer David Rodman - Chief Medical Officer Conference Call Participants Michael DiFiore - Evercore Richard Law - Goldman Sachs Annabel Samimy - Stifel Rami Katkhuda - LifeSci Capital Matthew Caufield - H.C. Wainright Operator Greetings.
Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
– Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025 – – Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025 – – Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences.
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024.
Mineralys Therapeutics Inc Is Being Investigated For Securities Law Violations And Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Encourages Investors To Join An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Mineralys Therapeutics Inc Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Encourages Investors To Take Part In An Inquiry Into Mineralys Therapeutics, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Encourages Investor Participation In An Inquiry Into Mineralys Therapeutics Inc For Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Mineralys Therapeutics, Inc. Is Being Investigated For Securities Law Violations And Affected Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Encourages Investors To Take Part In An Inquiry Into Mineralys Therapeutics Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Mineralys Therapeutics, Inc. ("Mineralys" or "the Company") (NASDAQ:MLYS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for MLYS.